Adagene CEO to Present Clinical Update on October 15
The leadership at the San Diego-based biotech will discuss its clinical development programs during a virtual industry conference.
Updated on Oct. 14, 2026 in Biotech

On October 15, 2026, Adagene CEO Peter Luo will participate in a fireside chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference. The session will cover clinical development progress for the company's platform.
Why it matters
The session provides visibility into the current progress of clinical-stage immunotherapy pipelines, which rely on proprietary library technology to refine drug targeting. Stakeholders look to these updates to gauge the advancement of ongoing trials in the competitive immuno-oncology space.
Adagene utilizes Dynamic Precision Library technology platforms to engineer therapeutic antibodies. The firm is currently evaluating Muzastotug, an anti-CTLA-4 SAFEbody, in Phase 1b/2 and Phase 2 clinical trials.
The players
Peter Luo
Chief Executive Officer and President of R&D at Adagene, overseeing the company's clinical research strategy.
Adagene
A clinical-stage biotechnology company developing antibody therapies using its proprietary library platforms.
The details
Adagene employs a Dynamic Precision Library — a proprietary platform for building and screening antibody libraries — to identify candidates with specific binding characteristics. Muzastotug is designed as an anti-CTLA-4 SAFEbody, a technology that enables an antibody to remain inactive until it reaches the specific tumor microenvironment, where it then becomes activated to mitigate potential toxicity.
Timeline
October 15, 2026: The fireside chat session takes place during the virtual conference.
October 15, 2026, 1:30 p.m. to 2:00 p.m. ET: Duration of the scheduled fireside chat.
30 days post-conference: The duration for which the session webcast remains available for viewing.
The Tech Race
The conference highlights the ongoing race to improve the safety and efficacy profiles of immune cell engagers through protein engineering. Adagene's participation follows a broader industry trend of validating clinical-stage platforms against traditional antibody-based therapies.
Investors and industry observers can access the session via a webcast available through the company's portal. This platform update offers insight into the clinical trajectory of the company's lead candidates, such as Muzastotug, following the conclusion of the event.
The takeaway
The event serves as a bellwether for the maturation of the company's proprietary protein-engineering platform and clinical trial outcomes. Observers should track the subsequent release of the webcast to verify reported progress in Phase 2 studies.
What happens next
A webcast of the fireside chat will be accessible on the investor website starting on October 15, 2026, and will remain available for a 30-day period.
Further reading
Learn more about the latest innovations in clinical development in the Biotech section.
More information
View the archived session details on the Adagene investor relations website.
Source note: This article includes information reported by The Manila times.





